Swiss National Bank Sells 48,400 Shares of DexCom, Inc. (NASDAQ:DXCM)

Swiss National Bank lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 4.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,132,000 shares of the medical device company's stock after selling 48,400 shares during the quarter. Swiss National Bank owned about 0.29% of DexCom worth $88,036,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Versant Capital Management Inc bought a new stake in shares of DexCom during the 4th quarter valued at $25,000. Private Trust Co. NA lifted its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares during the period. Larson Financial Group LLC grew its stake in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares in the last quarter. Heck Capital Advisors LLC acquired a new stake in shares of DexCom during the 4th quarter worth approximately $38,000. Finally, SBI Securities Co. Ltd. bought a new position in shares of DexCom in the 4th quarter valued at $49,000. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Trading Up 3.8 %

DXCM stock traded up $2.68 during mid-day trading on Wednesday, reaching $73.38. The company's stock had a trading volume of 4,301,549 shares, compared to its average volume of 3,887,223. The company has a market cap of $28.67 billion, a price-to-earnings ratio of 51.31, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The business's 50 day moving average price is $83.64 and its 200 day moving average price is $76.95. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

DXCM has been the subject of a number of research analyst reports. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and upped their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Morgan Stanley lifted their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Citigroup boosted their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Finally, Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $99.82.

Insider Activity

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 104,657 shares of company stock worth $8,019,422 over the last quarter. 0.30% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.